Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Katarina Steen Carlsson

University Name

Sweden

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Cardiology

40%

Health Economics

100%

Cardiometabolic Health

70%

Diabetology

50%

Coronary Artery Disease

30%

Cerebrovascular Disease

30%

Chronic Disease Management

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles17

Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries–Comparisons to Matched Controls

Article Link

Year:

2025

Brief admission by self-referral as an add-on to usual care for individuals with self-harm at risk of suicide: cost-effectiveness and 4-year health-economic consequences after a Swedish randomized controlled trial

Article Link

Year:

2024

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

Article Link

Year:

2024

Cardiovascular events, mortality, early retirement and costs in >50 000 persons with chronic heart failure in Sweden

Article Link

Year:

2024

Prevalence of diabetes and hospitalization due to poor glycemic control in people with bladder cancer or renal cell carcinoma in Sweden

Article Link

Year:

2024

Recombinant FVIII replacement products for haemophilia A: An updated valuation by indirect comparison measuring area under the curve

Article Link

Year:

2024

Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality

Article Link

Year:

2023

Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease

Article Link

Year:

2023

Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden

Article Link

Year:

2023

Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals

Article Link

Year:

2023

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A

Article Link

Year:

2023

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer

Article Link

Year:

2022

Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study

Article Link

Year:

2022

Current and future costs of obesity in Sweden

Article Link

Year:

2022

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden

Article Link

Year:

2020

Socioeconomic Factors in Patients with Ulnar Nerve Compression at the Elbow: A National Registry-Based Study

Article Link

Year:

2020

Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden

Article Link

Year:

2020

Collaborators10

Daiva Daukantaite

SWEDEN

Sahar Barjesteh van Waalwijk van Doorn

Leiden University Medical Center

NETHERLANDS

Lisa Rydén

Professor Surgery

Umeå Universitet Medicinska fakulteten

SWEDEN

Sofie Westling

lecturer

Lund University

SWEDEN

Johan Jendle

Professor

Örebro university

SWEDEN

Mattias Ohlsson

Professor

Lund University Samhällsvetenskapliga fakulteten

SWEDEN

Åslaug Helland

Professor

University of Oslo

NORWAY

Erika Nyman

Linköping University Hospital

SWEDEN

Björn Eliasson

University of Gothenburg

SWEDEN

Peter Lindgren

professor of health economics

Karolinska Institutet

SWEDEN

How do I reach out?

Meet Kite AI